Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis

. 2018 Jan ; 109 (1) : 174-181. [epub] 20171109

Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/pmid29055056

In the phase III RADIANT-4 study, everolimus improved median progression-free survival (PFS) by 7.1 months in patients with advanced, progressive, well-differentiated (grade 1 or grade 2), non-functional lung or gastrointestinal neuroendocrine tumors (NETs) vs placebo (hazard ratio, 0.48; 95% confidence interval [CI], 0.35-0.67; P < .00001). This exploratory analysis reports the outcomes of the subgroup of patients with lung NETs. In RADIANT-4, patients were randomized (2:1) to everolimus 10 mg/d or placebo, both with best supportive care. This is a post hoc analysis of the lung subgroup with PFS, by central radiology review, as the primary endpoint; secondary endpoints included objective response rate and safety measures. Ninety of the 302 patients enrolled in the study had primary lung NET (everolimus, n = 63; placebo, n = 27). Median PFS (95% CI) by central review was 9.2 (6.8-10.9) months in the everolimus arm vs 3.6 (1.9-5.1) months in the placebo arm (hazard ratio, 0.50; 95% CI, 0.28-0.88). More patients who received everolimus (58%) experienced tumor shrinkage compared with placebo (13%). Most frequently reported (≥5% incidence) grade 3-4 drug-related adverse events (everolimus vs. placebo) included stomatitis (11% vs. 0%), hyperglycemia (10% vs. 0%), and any infections (8% vs. 0%). In patients with advanced, progressive, well-differentiated, non-functional lung NET, treatment with everolimus was associated with a median PFS improvement of 5.6 months, with a safety profile similar to that of the overall RADIANT-4 cohort. These results support the use of everolimus in patients with advanced, non-functional lung NET. The trial is registered with ClinicalTrials.gov (no. NCT01524783).

Zobrazit více v PubMed

Yao JC, Hassan M, Phan A, et al One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–3072. PubMed

Detterbeck FC. Clinical presentation and evaluation of neuroendocrine tumors of the lung. Thorac Surg Clin. 2014;24:267–276. PubMed

Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology. 2004;80(Suppl 1):3–7. PubMed

Rekhtman N. Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med. 2010;134:1628–1638. PubMed

Oberg K, Hellman P, Ferolla P, Papotti M, Group EGW. Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2012;23(Suppl 7):vii120–vii123. PubMed

Granberg D. Neuroendocrine tumors of the lung In:Yalcin S, Öberg K, eds. Neuroendocrine Tumors: Diagnosis and Management. Berlin, Heidelberg:Springer‐Verlag;2015:143–164.

Filosso PL, Ferolla P, Guerrera F, et al Multidisciplinary management of advanced lung neuroendocrine tumors. J Thorac Dis. 2015;7:S163–S171. PubMed PMC

Krug LM, Kris MG, Rosenzweig K, et al Cancer of the Lung: small cell and other neuroendocrine tumors of the lung In:DeVita VT, Lawrence TS, Rosenberg SA, Weinberg RA, Depinho RA, eds. Cancer Principles and Practice of Oncology. Alphen aan den Rijn:Wolters Kluwer, Lippincott Williams and Wilkins;2008:946–971.

Pavel M, O'Toole D, Costa F, et al ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103:172–185. PubMed

Filosso PL, Ruffini E, Oliaro A, Papalia E, Donati G, Rena O. Long‐term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide. Eur J Cardiothorac Surg. 2002;21:913–917. PubMed

Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller‐Brand J. The clinical value of [90Y‐DOTA]‐D‐Phe1‐Tyr3‐octreotide (90Y‐DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol. 2001;12:941–945. PubMed

Mariniello A, Bodei L, Tinelli C, et al Long‐term results of PRRT in advanced bronchopulmonary carcinoid. Eur J Nucl Med Mol Imaging. 2016;43:441–452. PubMed

Kulke MH, Lenz HJ, Meropol NJ, et al Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol. 2008;26:3403–3410. PubMed

Grande E, Capdevila J, Castellano D, et al Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open‐label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). Ann Oncol. 2015;26:1987–1993. PubMed

Yao JC, Phan A, Hoff PM, et al Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha‐2b. J Clin Oncol. 2008;26:1316–1323. PubMed

Brizzi MP, Berruti A, Ferrero A, et al Continuous 5‐fluorouracil infusion plus long acting octreotide in advanced well‐differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network. BMC Cancer. 2009;9:388. PubMed PMC

Bajetta E, Catena L, Procopio G, et al Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low‐grade and high‐grade neuroendocrine tumours? Cancer Chemother Pharmacol. 2007;59:637–642. PubMed

Ekeblad S, Sundin A, Janson ET, et al Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res. 2007;13:2986–2991. PubMed

Fazio N, Granberg D, Grossman A, et al Everolimus plus octreotide long‐acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo‐controlled RADIANT‐2 study. Chest. 2013;143:955–962. PubMed

Yao JC, Lombard‐Bohas C, Baudin E, et al Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol. 2010;28:69–76. PubMed PMC

Yao JC, Shah MH, Ito T, et al Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514–523. PubMed PMC

Yao JC, Fazio N, Singh S, et al Everolimus for the treatment of advanced, non‐functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT‐4): a randomised, placebo‐controlled, phase 3 study. Lancet. 2016;387:968–977. PubMed PMC

Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39:707–712. PubMed

Rindi G, Arnold R, Bosman FT, et al Nomenclature and classification of neuroendocrine neoplasm of the digestive system In:Bosman FT, Carniero F, Hruban RH, Theise ND, eds. WHO Classification of Tumours of the Digestive System, 4th edn Lyon:International Agency for Research on Cancer;2010:13–14.

Hendifar AE, Marchevsky AM, Tuli R. Neuroendocrine tumors of the lung: current challenges and advances in the diagnosis and management of well‐differentiated disease. J Thorac Oncol. 2017;12:425–436. PubMed

Pelosi GFA, Cossa M, et al What clinicians are asking pathologists when dealing with lung neuroendocrine neoplasms? Semin Diagn Pathol. 2015;32:469–479. PubMed

Ferolla P, Brizzi MP, Meyer T, et al Efficacy and safety of pasireotide LAR or everolimus alone, or in combination in patients with advanced carcinoids (NET) of the lung/thymus: results from the randomized, phase 2 LUNA study. Ann Oncol. 2016;27:136–148.

Yao JC, Fazio N, Singh S, et al Everolimus (EVE) in advanced, nonfunctional, well‐differentiated neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin: second interim overall survival (OS) results from the RADIANT‐4 study. J Clin Oncol. 2016;34:4090.

Zobrazit více v PubMed

ClinicalTrials.gov
NCT01524783

Najít záznam

Citační ukazatele

Možnosti archivace